Gilead Sciences, Inc. (NASDAQ:GILD) has seen its stock price gain 1.21, or +1.69%, so far in 2017. In the past 3-month period alone, shares of GILD have appreciated -0.52 – or -0.71%. The stock’s 52-week range is $63.76 to $86.27, and its 3-month range is $70.05 to $86.27.The average Wall Street analyst rating for Gilead Sciences, Inc. is Hold, according to the average of 22 analyst scores. Of those analysts, 10 rate stock as a Strong Buy, 11 rate it as Hold, and just no analyst rates it as a Moderate Sell.Insider Trading Activity for Gilead Sciences, Inc.Looking at a public company’s insider trading can give great insight into how the stock is performing. Gilead Sciences, Inc. has had 20 insider trades in the last 3 months, including 4 open market buys and 16 sells. Of those insider trades, 13,125 shares of Gilead Sciences, Inc. were purchased and 817,311 shares were sold. The total number of shares traded in the last 90-day period is 830,436.
     (adsbygoogle = window.adsbygoogle || []).push({});
Insider trading over the last 12 months, however, paints a different picture. In the last year there have been a total of 72 insider trades, including 24 open market buys and 48 sells. Of those transactions, there were 112,434 shares of GILD bought and 1.71 million shares sold. The total number of shares traded in the last 12 months is 1.82 million.The most recent open market insider trade was Sell of 220,000 shares on a day where the closing price was 72.88. The insider, MILLIGAN JOHN F, now holds 1.17 million shares of GILD.The most recent non open market insider trade was completed by BISCHOFBERGER NORBERT W on 11/20/2017, and was a disposition of 10,000 shares with a final price of $0. The insider now holds 2.31 million shares of Gilead Sciences, Inc. (GILD).Examining Institutional Ownership at Gilead Sciences, Inc. (NASDAQ:GILD)According to Gilead Sciences, Inc.’s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 77.52%. The total amount of shares outstanding is 1.31 billion, giving the company a market capitalization of about 95.06 billion.There are 1,642 institutional holders with active positions, accounting for 1.01 billion shares in total. Of those holders, 723 had increased positions amounting to 96.84 million shares, 750 had decreased positions amounting to 68.53 million shares, and 169 holders have a held position accounting for 847.25 million shares.The top 5 institutional holders, in ascending order, are as follows: BLACKROCK INC. with 102.24 million shares, VANGUARD GROUP INC with 94.53 million shares, STATE STREET CORP with 55.41 million shares, BANK OF NEW YORK MELLON CORP with 30.1 million shares, and FMR LLC with 27.71 million shares.According to Gilead Sciences, Inc. (GILD) most recent 13F filing, the company has 118 new institutional holders – accounting for 12.55 million shares of its common stock. There were 123 sold out positions, amounting to 10.42 million shares.



(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});


Economy and Money Authors gives investors their free and unbiased view of Financial Markets and on what happening in Stock Market. Our team certainly analyze tons of Stocks every day and provide their fair opinion on them. We are always looking over financial statements, company’s earning, analyst upgrades/downgrades, joint ventures and balance sheets to keep our reader up to date.